euangelion.THE DAILY EDITION
Edition
25 stories
THE EDITION

From the city to the frontier.

25 stories found
01

San Francisco

The life of the city

3 stories
02

United States

Possibilities taking shape

4 stories
Cancer care · A longer interval before progression

Tucatinib gains a maintenance indication for advanced HER2-positive breast cancer

FDA approved tucatinib with trastuzumab and pertuzumab after induction treatment for advanced HER2-positive breast cancer; the trial delayed progression, while overall-survival data remain immature.

Read 3 sources · 1 min
A red and pink trastuzumab antibody binds a blue HER2 receptor that crosses a grey schematic cell membrane.
Blue HER2 crosses the grey cell membrane: outside above, inside below. Pink/red trastuzumab binds outside · Molecular illustration, April 2022.
03

Ukraine

Continuity. Reconstruction. Life.

3 stories
04

World

A wider perspective

6 stories
05

Artificial intelligence

New tools, considered

5 stories
06

Biotechnology × AI

At the edge of what we know

2 stories
Discuss in your voice app

Take the reporting, visual explanations and original sources into a conversation. Copy the brief, paste it into your preferred assistant, then start its voice mode.

Open ChatGPT
Paste the brief into your voice app to discuss this reporting.